Mechanism of Action
KOR Signaling and Dysphoria
KOR is a Gi-coupled GPCR expressed in the striatum (nucleus accumbens, caudate-putamen), prefrontal cortex, amygdala, and dorsal raphe. Dynorphin/KOR activation inhibits dopamine release in the nucleus accumbens, directly opposing the rewarding effects of dopamine. KOR also inhibits serotonergic neurons in the dorsal raphe. Together, these effects produce dysphoria, social withdrawal, and anhedonia -- the "dark side" of addiction when positive reinforcement wanes.
Stress-Induced Release and CRF Interaction
Stress activates CRF (corticotropin-releasing factor) neurons, which drive dynorphin release from nucleus accumbens shell neurons. This stress-dynorphin-KOR cascade is a key mechanism linking psychological stress to negative emotional states. Dynorphin also acts in a feedback loop with CRF: KOR activation in the amygdala further stimulates CRF release, amplifying stress responses. Breaking this loop with KOR antagonists is the rationale for trials in stress-related disorders.
Research Summary
Depression and Anhedonia
Phase 2/3Aticaprant (CERC-501, JNJ-67953964) Phase 2b in MDD: significant reduction in anhedonia and depression scores vs placebo in patients with high-anhedonia phenotype (MADRS anhedonia score). Phase 3 KOASTAL trials ongoing. Nalfurafine (Japan-approved KOR agonist for pruritus) demonstrates the separation of KOR effects -- itch reduction without full CNS dysphoria -- suggesting subtype-selective approaches.
Addiction and Substance Use
Phase 2KOR antagonists reduce alcohol intake, cocaine place preference, and stress-induced reinstatement in animal models. JDTic, ALKS-5461 (buprenorphine/ALKS-33 combination) Phase 2 in MDD/AUD. The dynorphin-driven "dark side" of addiction is a validated mechanism for the aversive states driving relapse; KOR blockade may reduce negative reinforcement motivation to use substances.
Analgesia (Complex Role)
Active ResearchSpinally, dynorphin/KOR produces antinociception; supraspinally and in the periphery, KOR activation can be pronociceptive or produce hyperalgesia after inflammation. KOR agonists with peripheral or spinal selectivity (CR845/difelikefalin, FDA-approved for CKD-associated pruritus) circumvent CNS dysphoria while providing analgesia and anti-itch.
Calculate your Dynorphin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| KOR agonism/pain research | 1-10 nmol intrathecal; 0.1-1 nmol/kg IV (rodent) | Per session | Intrathecal or intravenous |
| Stress model (negative affect) | 5-20 nmol ICV in forced swim/stress models | Per session | ICV |
No therapeutic use as exogenous dynorphin. Clinical applications focus on KOR antagonists for depression/addiction and peripherally restricted KOR agonists for itch/pain.
Interactions
Safety Profile
Exogenous dynorphin in research doses produces expected KOR effects: sedation, dysphoria, diuresis, analgesia. High-dose intrathecal dynorphin in rodents can be neurotoxic via non-opioid mechanisms involving NMDA receptors and neuroinflammation -- this is thought to contribute to chronic pain sensitization after spinal injury. KOR antagonists (aticaprant, buprenorphine) are well tolerated in clinical trials with mild GI effects as primary adverse events. No significant cardiotoxicity or organ damage identified.
References
- [1]Goldstein A, et al. Dynorphin-(1-13), an extraordinarily potent opioid peptide. Proc Natl Acad Sci USA. 1979;76(12):6666-6670.
- [2]Chavkin C. The therapeutic potential of kappa-opioids for treatment of pain and addiction. Neuropsychopharmacology. 2011;36(1):369-370.
- [3]Feeney A, et al. The kappa opioid receptor and the treatment of mood disorders: clinical evidence. J Psychopharmacol. 2023;37(3):235-252.